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Given the typical age onset of schizophrenia, there are tremendous economic and social
impacts that extend beyond the person and their families. One critical determinant of the
diseases’ impact is the patient’s adherence to antipsychotic drug treatment. Approved in
2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month
injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic
medication. Among the different formulations offered for palmitate paliperidone, including
the 1 and 3-month formulations, the longer duration 3-month formulation was better at
preventing relapse in schizophrenic patients. To date, different formulations of palmitate
paliperidone that have been studied on relapse episodes of schizophrenia include
once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly
paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M).
Post-hoc analyses show that patients who were withdrawn from PP1M paliperidone
had the least risk of relapse, followed by patients withdrawn from PP3M and patients
withdrawn from ORAL paliperidone. PP3M was better at preventing relapse compared to
ORAL paliperidone. The results demonstrated that 50% of patients who were withdrawn
from ORAL paliperidone, PP1M, or PP3M remained relapse-free for ∼2, 6, and 13
months, respectively. Compared to PP1M, PP3M is just as safe and effective and has the
added advantage of increased adherence related to a longer dose interval, decreasing
the risk of relapse.
Keywords: paliperidone, long-acting injectable, antipsychotic, schizophrenia, Invega Trinza
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INTRODUCTION

PP3M has shown a longer time to relapse and good safety
and tolerability in many studies (14). However, its approval was
met with resistance which highlighted concerns that this dosing
interval would lead to less frequent doctor visits which could
negatively affect the therapeutic relationship (15). This report
also argued that the longer dosing interval would actually lower
adherence to treatment as a whole (15). They concluded that
more clinical studies should be conducted prior to the approval
of PP3M to assess its safety and efficacy.
Two randomized control trials (RTCs) were used to elevate the
authorization of the 3-month injection of paliperidone palmitate
(PP3M). The first was by Berwaerts et al. which looked at PP3M
vs. placebo for relapse prevention in schizophrenia. This study
showed that the time to first relapse was significantly different
in the PP3M group when compared to placebo (16). The second
study was by Savitz et al. in 2016. This study was a double blind,
paraellel-group multicenter phase 3 trial that was designed to
test PP3M to the currently available 1-month formulation. The
patients in this study were previously stabilized on the 1-month
formulation. The authors found no clinically relevant differences
in pharmacokinetic exposures and that PP3M was non-inferior
to the 1-month with similar relapse rates (17). The authors
concluded that the PP3M could offer a unique dosing option for
relapse prevention in some patients. This manuscript examines
the use of PP3M which shows promise in preventing relapse rates
with its longer dosing interval and aims to examine the studies
regarding its safety, efficacy, and clinical utility as a narrative
review with the more current studies available.

Schizophrenia is a complex and often misunderstood mental
illness that can be severely debilitating if left untreated
(1). First characterized around the mid-to-late- 19th century,
schizophrenia was initially described as an early form of dementia
and was called “dementia praecox,” meaning “early dementia”
(2). In the early 20th century, the term “schizophrenia” was
used instead to distinguish mental illness from dementia and
other neuropsychiatric disorders (2). Since then, technological
and psychosocial advancements such as genetic testing and
cognitive-behavioral therapy have drastically improved the way
we understand and treat schizophrenia. However, certain aspects
of the disease remain a mystery (3, 4).
Affecting ∼1% of the world’s population, roughly 78 million
people worldwide and 2.4 million in the US, schizophrenia is
one of the top 15 leading causes of disability worldwide (5). The
disease often presents in early adulthood between the ages of 20
and 45, with men exhibiting symptoms in their early 20’s and
women in their mid-twenties to early 30’s (6, 7). For affected
people, all aspects of their daily lives are affected, and they have
a lower life expectancy and overall quality of life (1, 8). Given
the young age of onset in schizophrenia and the type of care
required for patients, there are remarkable economic and social
impacts that extend beyond the person and their families (9).
For example, it was estimated that in 2013, ∼$155 billion was
spent on direct and indirect costs associated with schizophrenia,
which is 2.5 times more than the approximate $62 billion spent in
2002 (8, 9). One critical determinant of the diseases’ impact is the
patient’s adherence to antipsychotic drug treatment, which can be
complicated by a number of isolated and interrelated factors such
as access to care and socioeconomic status (10). Consequently,
vulnerable patient populations such as low-income, minorities,
and the homeless are most at risk for relapses in treatment
related to lower medication adherence, resulting in uncontrolled
symptoms and ultimately poorer health outcomes (9).
The use of long acting injectables (LAI) is a debated topic
in the field of psychiatry. It is argued that the use of LAIs
very early in the course of treatment can be very desirable as
an estimated half of patients hospitalized for a first episode of
psychosis discontinue their medication after being discharged
(11). A study performed by Bartzokis et. al looked at the use
of oral risperidone and the use of an LAI on the impact of
intracortical myelination (ICM) trajectory in the first episode
of schizophrenia. The authors found the ICM volume increased
significantly in the LAI group and non-significantly in the oral
risperidone group (12). The authors suggest that using a LAI
may modify the ICM volume due to either better adherence to
the medications or a different pharmacokinetic profile. Another
study compared paliperidone palmitate, a 1-month LAI, with
oral antipsychotic therapy. The study found that paliperidone
palmitate was associated with a significant delay in time to first
treatment failure vs. oral antipsychotics with overall treatment
failure over 15 months being 38.8 vs. 53.7% (13). This study
illustrated the real world management of schizophrenia using a
1-month LAI which demonstrated a longer time to treatment
failure when compared to oral antipsychotics (13).

Frontiers in Psychiatry | www.frontiersin.org

SCHIZOPHRENIA BACKGROUND
Risk Factors
There is also an increased risk for future schizophrenia diagnosis
after a presentation of an unspecified psychosis. According to
Hensel et al., 1 in 4 persons diagnosed with unspecified psychotic
disorder will receive a schizophrenia diagnosis after 2 years
(18). Also, once patients have already been diagnosed with
schizophrenia and have begun treatment, relapse is a possibility
when patients are non-adherent to their regimens (19, 20).

Presentation
There are three classes of findings used to diagnose
schizophrenia: positive symptoms, negative symptoms, and
cognitive impairment (21). Positive symptoms are also referred
to as psychotic symptoms and are generally episodic in nature.
They include the presence of hallucinations, delusions, or bizarre
behaviors and/or beliefs. There are various classifications of
hallucinations and delusions, but the common denominator
is they all indicate a loss of contact with reality. According
to the DSM 5, hallucinations or delusions must be present
to indicate a diagnosis of schizophrenia. Negative symptoms,
on the other hand, are more consistent over time and are all
strongly associated with poor psychosocial functioning. These
symptoms include a diminish or absence of basic emotional
and behavioral states. For instance, monotonous vocal tone,
immobile facial expressions, and quality of speech are examples
of negative symptoms. The last set of findings in a patient
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cholinergic system by nicotinic a-7 receptors is used in the
control of cognitive functions associated with schizophrenia
(22). Therefore, nicotinic a-7 agonists have been suggested
as adjuncts to treatments that improve cognitive impairment
associated with schizophrenia (23). Nicotinic agonists are used
mainly for controlling the cognitive symptoms associated with
schizophrenia, whereas muscarinic agonists are used to control
the positive symptoms (22). The dysfunction of the glutamatergic
system contributes to the development of schizophrenia in terms
of negative symptoms, cognitive deficits and, possibly also
positive symptoms (23). Therefore, pharmacologic modulation
of this system is of great recent interest (27).
One question that can arise is, which drugs are more
effective at preventing relapses and treating schizophrenia as
compared to other drugs (28)? A nationwide cohort of ∼30,000
patients with schizophrenia showed that clozapine and longacting injectable antipsychotic medications prevented relapse
most effectively (28).
Another important consideration is how long should the
treatment be continued (29)? Relapse rates are extremely high
when antipsychotic treatment is discontinued, even when the
patient has suffered only a single episode of psychosis (30).
Even though relapse poses serious psychological and biological
consequences, there are currently no reliable predictors of relapse
(29). However, treatment continued for too long leads to a poorer
long-term outcome (31). Overall, whichever treatment is used for
the patient, it is still best for clinicians to maintain patients on
a constant low-dose, well-tolerated antipsychotic than stopping
patients completely (29).
The negative symptoms associated with schizophrenia
strongly affect functional outcomes; hence research and
development of new drugs are important (22). However,
attempts at developing anti-schizophrenia medications have had
limited progress in treating negative symptoms (26). Further
research is being conducted to elucidate how to improve
medications to better control these symptoms (22).

TABLE 1 | Basic mechanism of action of antipsychotics.
Class

Mechanism of action

First generation antipsychotics

D2 antagonists

Second generation

5HT2A/D2 antagonists
Rapid D2 dissociation
5HT1A agonism

with schizophrenia, the presence of cognitive impairment, are
relatively intuitive. These symptoms consist of difficulties with
learning, memory, attention, concentration, abstract thinking,
and problem-solving (21).

CURRENT TREATMENT OF
SCHIZOPHRENIA
Existing medications for the treatment of schizophrenia work
by improving only positive symptoms such as agitation,
hallucinations, delusions, and aggression (22). However,
these medications are not as effective at preventing negative
symptoms (23). Table 1 discusses antipsychotics.
The only known mechanism of action of medications that
are approved for the treatment of schizophrenia is the blocking
of dopaminergic neurotransmission (24). This has been seen
in studies looking at PET studies in patients with first break
schizophrenia. Kapur et al. looked at patients prior to receiving
haloperidol and 2 weeks after starting treatment. They found
patients showed a wide range of D2 occupancy and the greater
degree of receptor occupancy predicted clinical improvement
as well as such as hyperprolactinemia and extrapyramidal side
effects (25). This is consistent with the theory of a dysfunction
in dopaminergic neurotransmission.
Evidence suggests that not only is the dysfunction of
dopaminergic receptors responsible for the symptoms of
schizophrenia, but the pathogenesis of schizophrenia also
involves dysfunction of multiple signaling systems outside of
the dysfunction in dopaminergic signaling (26). These systems
mainly include glutamatergic, serotonergic, adrenergic, and
cholinergic signaling systems (23). Therefore, new medications
are being tested in Phase II and Phase III clinical trials that
work on serotonin, glutamate, adrenergic, and acetylcholinergic
receptors (23).
Examples of these drugs include brexpiprazole, RP-5063, and
eltroprazine, which work on the malfunctioning serotonergic
system (22). ADX-7114 modulates the glutamate system (26),
Neboglamine modulates the adrenergic system, and ABT-126
and encenicline modulate the cholinergic system (22).
The rationale behind inhibiting the dopaminergic
neurotransmission for the treatment of schizophrenia is by
inhibiting the dopamine D2 receptor in the mesolimbic pathway,
the psychotic symptoms of schizophrenia can be inhibited (23).
On the other hand, blocking the transmission of serotonin
can increase the release of dopamine in the prefrontal cortex
and improve negative symptoms and cognitive impairment
associated with schizophrenia (27). The agonism of the
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MECHANISM OF ACTION OF
PALIPERIDONE
Although the exact mechanism of action of paliperidone is
unclear, it is in a pathway similar to risperidone (32). That is
because paliperidone is the active metabolite of risperidone. The
difference between the two is the addition of a hydroxyl group
in paliperidone (32). Both risperidone and paliperidone have
similar binding affinities for certain receptor subtypes, there are
several distinctions that are pharmacological meaningful. The
differences are in the 5HT2A/D2 affinity and it is hypothesized
that this difference can affect mitochondrial movement and
therefore calcium homeostasis, synaptic plasticity, and neuronal
firing (32). In addition to these receptors, there is differential
binding to histamine, adrenergic, and cholinergic receptors.
Risperidone is thought to have antagonism at the alpha 1 and
alpha 2 adrenergic and H1 receiptors which may contribute
to the therapeutic response as well as its adverse effects (32).
Paliperidone, on the other hand, is thought to exhibit weaker
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Administration and Dosing

affinity for the alpha 1 and alpha 2 adrenergic receptors when
compared to risperidone. Other studies suggest that there is
no affinity of cholinergic, muscarinic, and beta 1 and beta 2
adrenergic receptors. Paliperidone has an affinity for 5HT1D,
5HT2B, 5HT7 and D3 receptors, however, the inhibition constant
values for binding to D2 and 5HT2A receptors are lower than
for risperidone (32). The PP3M formulation uses NanoCrystal
technology similar to its predecessor, the PP1M, but is superior
in its extended sustained release capability due to an increased
particle size (33).

PP3M can only be administered by a healthcare professional
and only using the thin wall needles provided in the INVEGA
TRINZA R or INVEGA SUSTENNA R kits (35, 36). One dose is
meant for a single intramuscular injection, and the syringe must
be shaken within 5 min of injection to prevent an incomplete
administration (35). If a patient misses an injection, they have
up to 2.5 and 3.5 months to receive their dose (36). For missed
doses of 3.5–4 months, the previously administered dose should
be given immediately and then continue with the 3-month
injections following this dose (36). For a missed dose of 4–9
months, they should not receive the next dose and must start a
re-initiation regimen, and for missed doses that are >9 months,
the patient will re-initiate treatment with PP1M before starting
again with PP3M (36).

PALIPERIDONE PALMITATE, 3-MONTH
FORMULATION
Paliperidone palmitate (Invega Trinza, a 3-month injection,
noted as PP3M) was approved by the U.S. Food and Drug
Administration (FDA) in 2015 for the treatment of schizophrenia
and is a second-generation (atypical) long-acting injectable
(LAI) antipsychotic medication (34). Its active ingredient is
paliperidone, an atypical antipsychotic that is the metabolite of
risperidone, another first-generation antipsychotics (9). At the
time of FDA approval, PP3M was the only antipsychotic LAI with
a 3-month interval and, in addition to treating schizophrenia,
is used for schizoaffective disorder and as an adjunct to mood
stabilizers or antidepressants in adults (34, 35).

Upcoming Advancement: 6-Month LAI
Recently, Janssen submitted a supplemental New Drug
Application (sNDA) to the FDA for a 6-month formulation
of Paliperidone Palmitate (PP6M) and will submit a Marketing
Authorization Application extension to the European Medicines
Agency (EMA) later this year (37). With an increased dosing
regimen interval, the PP6M formulation hopes to offer greater
flexibility and control to patients and providers for schizophrenia
treatment (37). Similar to the PP3M formulation, there will be a
transition period, and patients will have to be stabilized on the
PP1M and/or PP3M formulations (37).

Considerations When Prescribing
Patients taking PP3M must be closely monitored for changes
such as cognitive and/or motor impairment, weight, blood
levels, and decreased cardiovascular function, among others (12).
Atypical antipsychotics, in general, have a degree of metabolic
complications such as hyperlipidemia, hyperglycemia, and QT
prolongation. Additionally, certain populations are at a greater
risk for complications or death while using these medications,
including elderly patients with dementia-related psychosis and
with renal or hepatic impairment, Parkinson’s dementia, or Lewy
body dementia (35, 36). The safety and effectiveness in children
under 18 have not been established, and pregnant women should
be advised of the potential fetal risk (36).

MORTALITY IN STUDIES
In 2014, 32 out of ∼11,000 patients in Japan died shortly after
taking Xeplion, the brand name for PP1M in that country,
during post-marketing monitoring (38, 39). The reported causes
of death include sudden death (most cardiac in nature), suicide,
neuroleptic malignant syndrome, and other diseases such as
cancer (38, 40). An analysis of these deaths, funded by Janssen
Research & Development LLC., found that although there was
an increased mortality reporting rate in this population, there
was no significant difference in the mortality incidence rates
compared to those in interventional clinical studies in Japan
and in observational patient cohorts (39). Additionally, this
analysis found that more than 50% of those patients were of
advanced age (50+), more than 70% were at an increased
risk for cardiovascular disease, and many were taking multiple
antipsychotics (39). Therefore, the study concluded that the
observed death rate could not be definitively attributed to
Xeplion (39). However, the warning was given to not use this
LAI with other antipsychotics or in a mix that could be seen
as polypharmacy.
Furthermore, a meta-analysis conducted in 2016 reviewed 52
random control trials of various LAI antipsychotics (LAI-APs) to
assess the safety of LAIs and found no significant difference in
the incidence of death between LAI-APs and oral antipsychotics
or placebo treatment groups (40). When comparing the pooled
LAI-APs group to the placebo group within the first 13 weeks
of treatment, there was a downward trend in the mortality
rate, but the authors noted this trend with caution due to a

Transitioning Patients to PP3M
There is a transition period before starting PP3M to safely
introduce the medication to the patient (36). First, the patient
must be started on a trial of oral risperidone or paliperidone to
ensure tolerability and to monitor for potential side effects before
being transitioned to a LAI. Once an LAI is started, patients must
be stabilized on Invega Sustenna (PP1M), the 1-month version
of paliperidone palmitate, for at least 4 months, with the last
2 months at the same dose (35). Only then may patients be
converted to PP3M at a dose about 3.5 times higher than the last
administered dose of PP1M (35, 36). PP3M is then administered
in place of the next scheduled monthly injection, then every 3
months thereafter (35). The injection can be given either 1 week
early or 1 week late due to scheduling issues with the patient.
However, it is not approved for early injection due to treatment
failure or due to the drug “wearing-off ” early.

Frontiers in Psychiatry | www.frontiersin.org
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the patient population (20). PP3M has the added convenience of
only being required every third month as opposed to monthly.
Even when comparing the pharmacokinetics of the two, the
exposure for a 3.5-fold higher dose of PP3M is similar to the
corresponding dose of PP1M (36).

small sampling size (40). People with schizophrenia have an
increased risk of cardiovascular disease (CDV), and a significant
number of deaths result from CDV (41). This increased risk has
been long established, but numerous genetic, environmental, and
pharmacological factors complicate this relationship (42). In view
of this and the study’s results, it can be concluded that there
is no significant increased risk in the mortality rate while on
LAI-APs (40).

CLINICAL STUDIES: SAFETY AND
EFFICACY

PHARMACOKINETICS/
PHARMACODYNAMICS

Clinical studies have been conducted recently to highlight the
safety and efficacy of different medications used in the treatment
of schizophrenia, especially in scenarios of non-adherence and
lack of access (44). Of the many medications that have been
studied, the most extensively studied medication is palmitate
paliperidone, as it can be given in the injectable form and can be
given for a long period of time (33). One such study compared the
medication aripiprazole once-monthly 400 mg and paliperidone
palmitate once-monthly on the Heinrichs–Carpenter Quality-ofLife Scale (QLS) (45). QLS is an accepted health-related quality
of life measurement in schizophrenic patients (45). This study,
conducted over a period of 28 weeks, showed that patients who
had taken aripiprazole 400 mg had significant improvements in
the metrics measured in QLS as compared to schizophrenic
patients who were administered paliperidone palmitate (45).
Another similar study conducted demonstrated that among
the different formulations offered for palmitate paliperidone,
including the 3-month formulation and 1-month formulation,
the 3-month formulation was better at preventing relapse
in schizophrenic patients (44). Furthermore, another study
conducted to compare the prevention in relapse in schizophrenic
patients offered palmitate paliperidone 3-month formulation
compared to placebo treatment showed that palmitate
paliperidone 3-month formulation was better at preventing
relapse (46). Moreover, schizophrenic patients who had been
administered PP3M had fewer reported hospitalizations for
psychiatric and social reasons as compared to patients who were
given placebo (47).
It is interesting to note that the efficacy of palmitate
paliperidone 3-month formulation was noted not only in the
American population but was also noted in the Latin American
population. A study conducted showed that Latin American
patients administered palmitate paliperidone showed no new
adverse effects as compared to American patients and patients
from all over the world (17).
Other studies done on palmitate paliperidone are concerned
with the half-life of the drug and relapse (48). The major
concern is if different formulations of the drug with different
half-lives affect schizophrenic patients who have discontinued
the medication (49). The different formulations of palmitate
paliperidone that have been studied to examine the effect of
half-lives on relapse episodes of schizophrenia include oncedaily extended-release oral paliperidone (ORAL paliperidone),
once-monthly paliperidone palmitate (PP1M), and once-every3-months paliperidone palmitate (PP3M) (48). Post-hoc analyses
have shown that patients who were withdrawn from PP1M
paliperidone had the least risk of relapse, followed by patients

Following injection, PP3M dissolves slowly due to it being
water-insoluble (36). After dissolving, paliperidone palmitate is
hydrolyzed to paliperidone and absorbed into the bloodstream.
The FDA reports that once in the bloodstream, the drug reaches
maximum plasma concentrations after a median of 30–33 days
(36). The distribution of the drug once in circulation varies
depending on injection site. Deltoid muscle injections showed an
11–12% higher maximum serum concentration on average than
gluteal muscle injections (36). In the same way, deltoid muscle
injections had a mean steady-state ratio of 1.7, with gluteal
muscle injections having a mean peak-to-trough ratio of 1.6 (36).
Overall, the drug has shown to have a volume of distribution of
about 1,960 L.
Similarly, half-life has proved to differ based on injection
site. The FDA reports a median half-life of 84–95 days
with deltoid administration and 118–139 days with gluteal
administration (36). One possible explanation for this extended
half-life is that the drug is not greatly metabolized by the
liver. If the provider notices that it seems to be “wearingoff ” early, they should consider gluteal over deltoid injections
for the previously stated reasons. The FDA demonstrated that
59% of an oral immediate-release paliperidone is excreted
unchanged a week after administration, insinuating that there
are no liver isozymes, largely impacting the metabolism of the
drug (36).

DIFFERENCE BETWEEN PP1M AND PP3M
PP1M (Invega Sustenna) and PP3M (Invega Trinza) are both
intramuscular injections of paliperidone palmitate used for longlasting treatment of Schizophrenia. PP3M is a 3-month injection,
meaning it is administered once every 3 months, while PP1M
is administered once a month (11). PP3M is indicated for
treatment only after patients have been treated with PP1M for
4 months, and it has shown to be effective and tolerated (43). The
key advantage of either paliperidone palmitate injection is that
they assist with non-compliance. Inconsistency with or absence
of maintenance therapy is a key factor related to relapse in
schizophrenia patients (19). Furthermore, up to 80% of patients
with schizophrenia do not adhere to medication regimens. This
can lead to hospitalization, episodes of psychotic behavior, and
overall negative burdens on not only patients but also their
families and society (20). Having long-lasting treatment options
available helps to alleviate some of the non-compliant aspects of
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TABLE 2 | Summary of clinical studies.
References

Phase or purpose

Methods

Outcome

Savitz et al. (44)

Phase 3

17-week, flexible-dosed, open-label phase
[PP1M: day 1 (150 mg eq. deltoid), day 8
(100 mg eq. deltoid.), weeks 5, 9, and 13
(50, 75, 100, or 150 mg eq.,
deltoid/gluteal)], clinically stable patients
were randomized (1:1) to PP3M
(fixed-dose, 175, 263, 350, or 525 mg eq.
deltoid/gluteal) or PP1M (fixed-dose, 50,
75, 100, or 150 mg eq. deltoid/gluteal) for
a 48-week double-blind phase

PP3M was non-inferior to PP1M: relapse rates
were similar in both groups [PP3M: n = 37,
8%; PP1M: n = 45, 9%; difference in
relapse-free rate: 1.2% (95% CI:-2.7%; 5.1%)]
No clinically relevant differences were observed
in pharmacokinetic exposures between PP3M
and PP1M.

Ravenstijn et al. (34)

Phase 1

Multicenter, randomized, open-label,
parallel-group study.
A total of 328 patients (men or women,
aged 18–65 years) were enrolled in 1 of 4
separately conducted panels (A–D). Each
panel had 2 single-dose treatment periods
[period 1, 1 mg intramuscular paliperidone
immediate release (IR); period 2,
intramuscular PP3M 75-525 mg eq]
separated by a washout of 7–21 days

Peak paliperidone plasma concentration was
achieved between 23 and 34 days, and
apparent half-life was ∼2–4 months
Headache and nasopharyngitis were the most
common (>7%) treatment-emergent
adverse events. Safety and tolerability were
similar to those of the 1-month formulation.

Naber et al. (45)

Head-to-head study with
aripiprazole

28-week, randomized, non-inferiority,
open-label, rater-blinded study between
400 mg of aripiprazole monthly injection
(AOM 400) and paliperidone palmitate one
monthly injection (PP)
Primary endpoint assessed non-inferiority
and superiority on QLS total score
analyzed using a mixed model for
repeated measurements

Statistically significant least squares mean
difference in change from baseline to week 28
on QLS total score [4.67 (95% CI: 0.32; 9.02),
p = 0.036] confirmed non-inferiority and
established superiority of AOM 400 vs. PP

Bell Lynum et al. (46)

Comparison of PP3M to placebo
to time of relapse

Patients received either PP3M or placebo
every 3 months in the double bind phase.
The primary efficacy variable was time
from randomization to first relapse

A total of 119 patients who entered the double
blind phase met the criteria for early illness
schizophrenia (PP3M, n = 62; placebo, n =
57). PP3M significantly delayed time to relapse
vs. placebo (P = 0.035; hazard ratio, 3.08;
95% CI, 1.08–8.80)

Chirila et al. (47)

Two Phase 3 trials

Occupational status was assessed at
each study visit. Logistic regressions
modeled the probability of hospitalization
during the double-blind phase

At the start of each study, a low percentage of
patients were full-time employed or gainfully
self-employed (∼10% in trial 3012 and 11–13%
in trial 3011)
Improvement from baseline in occupational
status was slightly higher in the PP3M group
than in placebo or PP1M groups. Odds of a
hospitalization for psychiatric and social
reasons during 1 year was 7.74 (95% CI,
2.39–25.05; p < 0.001) for a patient on
placebo compared with the odds of
hospitalization during 1 year for a patient
on PP3M.
No statistically significant difference was
observed between PP3M and PP1M (odds
ratio, 1.16; 95% CI, 0.70–1.93).

Savitz et al. (17)

Subanalysis of two phase 3 trials

Patients were randomized to PP3M or
PP1M (non-inferiority study A) and PP3M
or placebo (study B) in double blind phase.
The subgroup analysis included Latin
American (Argentina, Brazil, Colombia,
Mexico) patients

In study A, relapse-free percentage was similar
in Latin America (PP3M: 97%, PP1M: 100%)
and rest of world (ROW) (PP3M: 91%,
PP1M: 89%).
In study B, median time-to-relapse was not
estimable in the Latin American subgroup for
either placebo or PP3M groups, nor for the
ROW PP3M group; the median time-to-relapse
in the ROW placebo group was 395 days
(Continued)
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TABLE 2 | Continued
References

Phase or purpose

Methods

Outcome

Weiden et al. (48)

Examined difference between the
three formulations paliperidone

Data were drawn from 3 similarly
designed, multicenter, double-blind,
placebo-controlled,
randomized-withdrawal studies of
paliperidone in adults with a schizophrenia
diagnosis (according to DSM-IV criteria for
≥1 year before screening): once-daily
extended-release oral paliperidone (ORAL
paliperidone), once-monthly paliperidone
palmitate (PP1M), and
once-every-3-months paliperidone
palmitate (PP3M).

Postwithdrawal median [95% confidence
interval (CI)] days to relapse were 58 days
(42–114 days) for ORAL paliperidone, 172 days
(134–222 days) for PP1M, and 395 days (274
days-not reached) for PP3M (P < 0.0001,
pairwise comparisons).
Relapse risk was significantly lower (P < 0.001)
for patients who withdrew from either PP
formulation relative to ORAL paliperidone and
additionally for patients who withdrew from
PP3M relative to PP1M.

Mathews et al. (50)

Post-hoc, subgroup analysis

Patients were treated with PP1M [50, 75,
100, or 150 mg equivalent (eq.)] for 17
weeks during an open-label (OL) phase
and randomized (1:1) to PP3M (175, 263,
350, or 525 mg eq.) or PP1M (50, 75, 100,
or 150 mg eq.) during a 48-week
double-blind phase.

Improvements in Positive and Negative
Syndrome Scale (PANSS) scores (OL
baseline-to-endpoint) were similar in
recent-RIS/PALI (oral r isperdal/ paliperidone)
[mean (standard deviation):18.3 (17.96)] and
no-RIS/PALI [−21.1 (16.40)] subgroups
Relapse-free rates were comparable between
recent-RIS/PALI [relapse-free rate (95%
confidence interval for difference): 2.6 (−4.7 to
10.0); PP3M: 90%; PP1M: 87%] and
no-RIS/PALI subgroups [0.8 (−4.5 to 6.0);
PP3M: 92%; PP1M: 91%]

Kern Sliwa et al. (51)

Assessment of site pain

Patients (n = 1,429) with schizophrenia,
treated with PP1M [50–150 mg-eq,
17-week open-label (OL) phase] were
randomized to PP1M or PP3M for
48-weeks

Incidence of induration, redness, and swelling
were low in both phases (OL: 9–12%; DB:
7–13%), and were mostly mild in both groups

Assessed symptomatic and functional
remission achieved following paliperidone
palmitate 3-month (PP3M) vs. 1-month
(PP1M) treatment in patients (age: 18–70
years) with schizophrenia, previously
stabilized on PP1M

Functional remission was assessed using
Personal and Social Performance scale (PSP).
More than 50% patients in both groups
achieved symptomatic remission (PP3M:
50.3%; PP1M: 50.8%) during last 6 months of
double blind phase.
Similar percentage of patients of both groups
achieved functional remission (defined as PSP
score > 70, PP3M: 42.5%; PP1M: 43.9%) and
combined remission (symptomatic and
functional remission, PP3M: 25.1%; PP1M:
26.6%) during last 6 months of double
blind phase

Retrospective analysis included pooled
data from 651 subjects from one phase I
study (single injection of the 3-month
formulation) and one phase III study
(multiple injections of both 1- and 3-month
formulations)

The apparent volume of distribution estimated
for the 3-month formulation was not the same
as for the previously modeled
1-month formulation
Apparent clearance (CL), apparent volume of
distribution (V), and fraction of the absorbed
dose (F3 ) were estimated to be 3.84 l/h,
1,960 L, and 20.9%

Savitz et al. (52)

Magnusson et al. (53)

To characterize the population
pharmacokinetics of paliperidone
after intramuscular
administration of its long-acting
3-month formulation palmitate

two in these parameters is negligible (33, 50). Studies have
also interestingly shown no difference in injection site pain
between the two formulations regardless of dosage difference
and volume difference (51). The studies also clarify that giving
these medications once every 3 months is the best way to prevent
relapse in schizophrenic patients (33). PP3M is still preferable
as it has a longer dosing interval and thus can provide a unique
treatment option to help patients achieve improvement in
symptoms (52).

withdrawn from PP3M and patients withdrawn from ORAL
paliperidone (48). PP3M was better at preventing relapse
compared to ORAL paliperidone. The results demonstrated that
50% of patients who were withdrawn from ORAL paliperidone,
PP1M, or PP3M remained relapse-free for ∼2, 6, and 13 months,
respectively (48).
Studies that have assessed and compared the
pharmacokinetics, safety, and tolerability of PP3M with
PP1M have shown that the overall difference between the
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Retrospective analyses of population pharmacokinetics of
paliperidone using a one-compartment model have shown the
apparent clearance (CL), apparent volume of distribution (V),
and a fraction of the absorbed dose (F3) to be approximately
around 3.84 l/h, 1,960 L and 20.9%, respectively (53). These
parameters change accordingly if there is rapid or slow
absorption (53). Hence, this study supports the two saturable
absorption hypothesis to be applicable for paliperidone after
intramuscular administration of its long-acting 3-month
formulation, palmitate ester (53). This study was also crucial
as it highlighted that factors such as age, race, sex, body mass
index, and injection site do not affect the pharmacokinetics
and steady-state of paliperidone in patients undergoing such
treatment (53). However, the study did show that the renal status
of the patient did affect how well the drug was cleared (53).
Table 2 summarizes the studies discussed in this section.

negative symptoms (22, 23). However, the use of antipsychotic
treatments is necessary to correct the dopamine imbalance,
which will yield better results in psychosocial rehabilitation
(20). Difficulty in medication management can affect and
even derail long-term treatment goals for patients (9, 19).
However, PP3M, and potentially the PP6M formulation, offers
hope in treatment management. Compared to PP1M, PP3M
is just as safe and effective but with the added advantage of
increased adherence due to a longer dose interval, decreasing
the risk of relapse (19, 44, 48). Despite some safety concerns
regarding LAIs and PP3M, the data does not show a significant
risk of death in patients taking PP3M or LAIs (38–40).
Additionally, many confounding variables contributing to the
lowered life spans of individuals with schizophrenia must be
taken into account (8). Nevertheless, PP3M is an effective,
long-acting treatment option that is enabling patients and
providers to focus less on medication adherence and more
on the treatment plan and long-term goals (34). Prescribers
must consider that not all patients will respond to a LAI
and may have to consider other atypical medication trials
if the symptoms are not able to be controlled with the
PP3M. More research should be done to assess the long term
effects of the use of LAIs and to either confirm or refute
PP3M, as well as other LAIs, as being a way to prevent
disease relapse.

CONCLUSION
Schizophrenia is a complex and challenging psychiatric disorder
involving a number of dysfunctions with interplaying biological
and environmental factors (3, 20). Since its first description in
the 19th century, the understanding of schizophrenia has vastly
improved and expanded thanks to technological advancements
such as gene linkage studies and diagnostic tools such as the
DSM (54). Conversely, as research progresses in the classification
and treatment of schizophrenia, certain aspects (i.e., treatment
options) of the disease remain limited, and more unknowns
persist, such as the etiopathogenesis (54).
Pharmacotherapy remains the key treatment for
schizophrenia despite only treating the positive and not the
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